促性腺激素释放激素激动剂类药物缓控释制剂研究进展  

Sustained-and controlled-release pharmaceutical preparations of gonadotropin-releasing hormone agonists

作　　者：宋芸[1] 钟霞[1] SONG Yun ZHONC Xia(Hainan Medical University, Hainan Provincial Key Laboratory of Research and Development of Tropical Medicinal Plants, Haikou 571199, China)

机构地区：[1]海南医学院海南省热带药用植物研发重点实验室,海口571199

出　　处：《中国新药杂志》2017年第3期300-303,共4页Chinese Journal of New Drugs

基　　金：海南省自然科学基金(814287);国家级大学生创新实验项目(201511810003);海南省医学院大学生创新实验项目(HYCX2014007)

摘　　要：促性腺激素释放激素激动剂(GnRH-A)类药物是一大类人工合成的九肽或十肽药物,其临床主要用于治疗前列腺癌、乳腺癌、子宫内膜异位症、先天性中枢性早熟症、促排卵及治疗妇女不孕症等。该类药物的剂型主要为长效缓控释微球或埋植体,其辅料多为生物可降解的高分子材料。现就目前市场上常见的缓控释促性腺激素释放激素激动剂类药物的制剂组成及特点进行综述。Gonadotropin-releasing hormone agonists（GnRH-A） are a class of synthetic nona-or decapeptide drugs. They are widely used in the treatment of prostate cancer,breast cancer,endometriosis,congenital central precocious puberty disease, promoting ovulation and infertility, et al. Long-acting controlled-release microspheres or implants are the two main drug formulations for GnRH-A,and the main excipients are biodegradable polymer materials. Herein,the composition and characteristics of common marketed sustained-and controlledrelease pharmaceutical preparations of GnRH-A drugs are reviewed.

关 键 词：促性腺激素释放激素 激动剂 寡肽药物 缓控释微球 埋植体 

分 类 号：R979.1[医药卫生—药品]